Bavarian Nordic scraps RSV vaccine after PhIII trial misses the bar on preventing severe symptoms
Bavarian Nordic is scrapping its RSV program after its vaccine candidate flunked a large Phase III trial that had enrolled more than 20,000 elderly patients.
Its vaccine, MVA-BN RSV, flunked a co-primary endpoint in the study — the candidate only showed a 42.9% efficacy in preventing more severe symptoms of lower respiratory tract disease. MVA-BN RSV did hit the other primary endpoint, demonstrating a 59% efficacy in preventing at least two symptoms of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
